Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours

Annals of Oncology

Volumn 14, Issue 4, 2003, Pages 630-637

  Bennouna, J ^a   Fumoleau, P ^a   Armand, J P ^b   Raymond, E ^b   Campone, M ^a   Delgado, F M ^c   Puozzo, C ^c   Marty, M ^c  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Dose proportionality; Pharmacokinetics; Phase I study; Safety; Vinflunine

Indexed keywords

VINCA ALKALOID; VINFLUNINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VINBLASTINE;

ADULT; AGED; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MOUSE; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TIME; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MOUTH MUCOSA; NEOPLASM; PATHOLOGY; PHASE 1 CLINICAL TRIAL; STOMATITIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CONSTIPATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOUTH MUCOSA; NEOPLASMS; NEUTROPENIA; STOMATITIS; VINBLASTINE;

EID: 0037819331     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg174     Document Type: Article

References (16)

1. Fahy J, Duflos A, Ribet JP et al. Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J Am Chem Soc 1997; 119: 8576-8577.
2. Hill BT, Fiebig HH, Waud WR et al. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumor xenografts. Eur J Cancer 1999; 35: 512-520.
3. Kruczynski A, Colpaert F, Tarayre JP et al. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated vinca alkaloid. Cancer Chemother Pharm 1998; 41: 437-447.
4. Ngan VK, Bellman K, Panda D et al. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 2000; 60: 5045-5051.
5. Kruczynski A, Barret JM, Etiévant C et al. Antimitotic and tubulin-interacting properties of vinflunine, a novel vinca alkaloid. Biochem Pharmacol 1998; 55: 635-648.
6. Etiévant C, Kruczynski A, Chansard N et al. Characterization of apoptosis induced by vinflunine, a novel fluorinated vinca alkaloid, in sensitive and vinflunine resistant P388 tumor cells: concomitant cell cycle analysis. Proc Am Assoc Cancer Res 1998; 39: 166 (Abstr 1140).
7. Ngan VK, Bellman K, Hill BT et al. Mechanism of mitotic block and inhibition of cell proliferation by semisynthetic vinca alkaloids vinorelbine and its new derivative vinflunine. Mol Pharmacol 2001; 60: 225-232.
8. Lobert S, Ingram JW, Hill BT et al. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 1998; 53: 908-915.
9. Etiévant C, Barret JM, Kruczynski A et al. Vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel vinca alkaloid, which participates in P-glycoprotein (Pgp) mediated multidrug resistance in vivo and in vitro. Invest New Drugs 1998; 16: 3-17.
10. 2. 6èmes Journées du Groupe de Pharmacologie Clinique en Oncologie, October 1996, Ajaccio, France.
11. Khayat D, Covelli A, Variol P. Phase I and pharmacologic study of intravenous vinorelbine in patients with solid tumours. Proc Am Soc Clin Oncol 1995; 14: 469 (Abstr 1518).
12. Vantongelen K. A Practical Guide to EORTC Studies. Brussels, Belgium: EORTC Central Office and Data Centre 1994.
13. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
14. Fumoleau P, Raymond E, Bennouna J et al. Phase I trial of vinflunine a novel fluorinated vinca alkaloid in patients with advanced solid malignancies: final results. Proc Am Assoc Cancer Res 2001; 42: 834 (Abstr 4478).
15. Fumoleau P, Armand JP, Marty M et al. Pharmacokinetics of vinflunine a novel vinca alkaloid, during the phase I dose escalation study (D1 Q 3 weeks). Proc Am Assoc Cancer Res 2001; 42: 381 (Abstr 2050).
16. Barret JM, Etiévant C, Hill BT. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol 2000; 45: 471-476.